Combined modality program with possible organ preservation for invasive bladder carcinoma: Results of rtog protocol 85-12

摘要: Abstract Purpose: This Phase II study was designed to test the tolerance and effectiveness of concurrent cisplatin-radiotherapy in treatment invasive bladder cancer. Objectives were determine toxicity, complete response rate, preservation survival. Methods Materials: Patients with cancer, clinical Stages T2–4, NO-2 or NX, MO treated pelvic radiotherapy 40 Gy 4 weeks cisplatin 100 mg/m 2 on days 1 22. Complete responders given an additional 24 boost plus a third dose cisplatin; patients residual tumor after assigned radical cystectomy. Results: The remission rate following for evaluable cases 3147 (66%). Acute toxicity acceptable only two not completing induction therapy. poorly differentiated tumors more likely achieve remission. Of fully patients, 2842 (67%) achieved therapy, 11 remain continuously remission, eight have relapsed as site failure. Five these noninvasive tumor. 14 who failed three disease-free. Median survival is reached, 1742 (1948) deaths reported. Actuarial 64% at 3 years. Conclusion: combined regimen moderately well-tolerated associated clearance 66% treated. Isolated recurrences carcinoma are infrequent. Better definition pretreatment selection criteria needed if modality disease control organ